Loading…
BioRestorative Therapies, Inc. is projected to rise to $0.449 by 2027, a +4% move from its current price of $0.4329. BRTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.4009 | $0.4328 | $0.4671 | -0.03% |
| May 30 | $0.3883 | $0.4326 | $0.482 | -0.07% |
| May 31 | $0.3788 | $0.4325 | $0.4937 | -0.10% |
| Jun 1 | $0.371 | $0.4323 | $0.5038 | -0.14% |
| Jun 2 | $0.3642 | $0.4322 | $0.5128 | -0.17% |
| Jun 3 | $0.3582 | $0.432 | $0.521 | -0.20% |
| Jun 4 | $0.3528 | $0.4319 | $0.5287 | -0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3528 | $0.4319 | $0.5287 | -0.24% |
| Week 2 | $0.3236 | $0.4308 | $0.5736 | -0.48% |
| Week 3 | $0.3027 | $0.4298 | $0.6102 | -0.71% |
| Week 4 | $0.2861 | $0.4288 | $0.6427 | -0.95% |
| Week 5 | $0.2721 | $0.4278 | $0.6725 | -1.19% |
| Week 6 | $0.26 | $0.4267 | $0.7005 | -1.42% |
| Week 7 | $0.2492 | $0.4257 | $0.7271 | -1.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders.
Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc.
and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
BioRestorative Therapies, Inc. (BRTX) is a healthcare company focused on developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells.
The stock currently trades at $0.4329 and has a market cap of $11.03M. It is ranked 5069 in market capitalization lists.
Forecasts point to a path of price evolution with gradual near-term stabilization and longer-term upside, including an average price of $0.4329 in 2026, rising through mid-term years and reaching an average of $1.93 by 2050, with progressively higher max targets along the way.
A major floor 81.0% below — a decisive break under it would weaken the trend.
The nearest floor, 60.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 166.8% above — clearing it would confirm fresh momentum.
Key BRTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BRTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.2507 | Buy | $0.2859 | Buy |
| MA 10 | $0.2191 | Buy | $0.2473 | Buy |
| MA 20 | $0.2211 | Buy | $0.2332 | Buy |
| MA 50 | $0.2443 | Buy | $0.2853 | Buy |
| MA 100 | $0.4828 | Sell | $0.4763 | Sell |
| MA 200 | $0.9437 | Sell | $0.7992 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 79.18 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 417.31 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 110.35 | Buy |
| Bollinger %B (20,2) | 1.48 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.78 | Sell |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 84.27 | Sell |
| Momentum (10) | 0.24 | Buy |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 0.30 | Buy |
| ADX (14) | 24.96 | Buy |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 80, indicating overbought momentum within a neutral sentiment framework.
The 50-day simple moving average is $0.2443 and the 200-day simple moving average is $0.9437, showing price sitting near the shorter-term average and well below the longer-term average.
Support sits at $0.1698 and resistance at $0.4329. The 30-day price range runs from $0.2615 to $0.7167, highlighting a recent trading band within which the stock has oscillated.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.1698 | $0.4329 | $0.5512 | 0% | Neutral | |
| $0.3232 | $0.449 | $0.6752 | +4% | Neutral | |
| $0.3087 | $0.4552 | $0.7277 | +5% | Neutral | |
| $0.4073 | $0.6323 | $1.06 | +46% | Bullish | |
| $0.4265 | $0.6937 | $1.21 | +60% | Bullish | |
| $0.3391 | $0.5763 | $1.04 | +33% | Bullish | |
| $0.3224 | $0.5714 | $1.06 | +32% | Bullish | |
| $0.2955 | $0.5453 | $1.04 | +26% | Bullish | |
| $0.307 | $0.5893 | $1.15 | +36% | Bullish | |
| $0.4015 | $0.801 | $1.60 | +85% | Bullish | |
| $0.3434 | $0.763 | $1.68 | +76% | Bullish | |
| $0.8663 | $1.93 | $4.43 | +345% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.1698 | $0.4329 | $0.517 | +0.00% |
| June 2026 | $0.374 | $0.4485 | $0.5573 | +3.61% |
| July 2026 | $0.344 | $0.4196 | $0.5348 | -6.44% |
| August 2026 | $0.3228 | $0.399 | $0.5184 | -4.92% |
| September 2026 | $0.3397 | $0.4245 | $0.5602 | +6.39% |
| October 2026 | $0.3427 | $0.4327 | $0.579 | +1.92% |
| November 2026 | $0.3171 | $0.4041 | $0.5473 | -6.61% |
| December 2026 | $0.313 | $0.4023 | $0.5512 | -0.43% |
Click any year to see its month-by-month BRTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BRTX is projected to trade between $0.1698 and $0.5512, averaging $0.4329 — a potential gain of 0% from today's $0.4329. A consolidation phase looks the most probable path here.
BioRestorative Therapies, Inc.'s 2027 outlook centres on $0.449, within a $0.3232 to $0.6752 range. That is up +4% on the projected 2026 average. That marks a +4% change versus current levels. Price action looks broadly range-bound.
By 2028, BRTX could reach as high as $0.7277, with a base case around $0.4552 and support toward $0.3087 — roughly +5% from $0.4329. A consolidation phase looks the most probable path here.
Expect BRTX to range from $0.4073 to $1.06 through 2029. The $0.6323 average target implies a +46% move from current prices. That is up +39% on the projected 2028 average. Momentum favours further upside here.
The BRTX price prediction for 2030 points to an average of $0.6937 (low $0.4265, high $1.21) — a potential gain of +60% on today's $0.4329. Buyers look set to stay in control over this stretch.
In 2031, BRTX is projected to trade between $0.3391 and $1.04, averaging $0.5763 — a potential gain of +33% from today's $0.4329. That is -17% versus the projected 2030 average. Momentum favours further upside here.
BioRestorative Therapies, Inc.'s 2032 outlook centres on $0.5714, within a $0.3224 to $1.06 range. That is -1% versus the projected 2031 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BRTX could reach as high as $1.04, with a base case around $0.5453 and support toward $0.2955 — roughly +26% from $0.4329. Momentum favours further upside here.
Expect BRTX to range from $0.307 to $1.15 through 2034. The $0.5893 average target implies a +36% move from current prices. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The BRTX price prediction for 2035 points to an average of $0.801 (low $0.4015, high $1.60) — a potential gain of +85% on today's $0.4329. Momentum favours further upside here.
In 2040, BRTX is projected to trade between $0.3434 and $1.68, averaging $0.763 — a potential gain of +76% from today's $0.4329. That is -5% versus the projected 2035 average. Buyers look set to stay in control over this stretch.
BioRestorative Therapies, Inc.'s 2050 outlook centres on $1.93, within a $0.8663 to $4.43 range. That is up +152% on the projected 2040 average. That marks a +345% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BRTX today (≈ 2,310.00231 BRTX) could be worth
$4,447.04
+$3,447.04 (+345%) by 2050 · US Dollar
Based on the average projected BRTX price of $1.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BRTXwould be worth at today's price.
$1,000 invested in BRTX on May 27, 2025 (≈ 558.65923 BRTX) would be worth
$241.84
-$758.16 (-75.8%) today · 0.24× · US Dollar
Based on a BRTX entry price of $1.79 vs. today's $0.4329.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.1698 | $2,549.47 | +154.9% |
| 1 month ago | $0.2327 | $1,860.34 | +86.0% |
| 3 months ago | $0.2314 | $1,870.79 | +87.1% |
| 6 months ago | $1.08 | $401.32 | -59.9% |
| 1 year ago | $1.79 | $241.84 | -75.8% |
| All time (5.0y) ago | $32.8 | $13.2 | -98.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BRTX forecast.
Our base-case forecast reaches $0.87 around 2050.
Implied market cap at $0.87: $22.17M
The multi-year forecast shows bullish momentum forming after a neutral near term. In 2029 the average price is $0.6323 with a 46.1% ROI and a bullish sentiment, followed by 2030 with an average of $0.6937 and a 60.3% ROI. The trajectory continues upward toward 2050, with an average of $1.93 and a 344.7% ROI, under bullish sentiment.
Earlier years show more modest gains, with 2026 at an average of $0.4329 (neutral), 2027 at $0.449, and 2028 at $0.4552. The forecast also highlights notable milestones such as 2030 max of $1.21 and 2035 max of $1.60 with strong bullish readings across several years.
Longer horizon values include 2040 with an average of $0.763 and a 76.3% ROI, and a 2050 min of $0.8663, max of $4.43, and an average of $1.93. These figures are estimates and reflect projected investor sentiment and price paths but are not guaranteed.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $0.6937, with a min of $0.4265 and a max of $1.21. The expected ROI is 60.3%, and the sentiment is BULLISH.
Near term the forecast is NEUTRAL (2026–2028), with a shift to BULLISH sentiment from 2029 onward. The 2029–2030 averages show notable upside, culminating in 2050 with an average of $1.93 and a max of $4.43.
Yes. The forecast's 2050 max price is $4.43, with a 2050 min of $0.8663 and an average of $1.93, under bullish sentiment.
The current price is $0.4329.
The 30-day range runs from a low of $0.2615 to a high of $0.7167.
BioRestorative Therapies, Inc. Community Discussion
0Share your BioRestorative Therapies, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.